Back

APOLLO - Apixaban for prophylaxis of thromboembolic outcomes in COVID-19.

28 August 2022 (11:15 - 11:35)
Organised by:
Congress Presentation Part of: Latest science in COVID and vaccination Anticoagulants ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Renato Lopes

Duke University Medical Center, Durham (United States of America)

2 More presentations in this session

Presentation thumbnail
Myocardial Inflammation/Myocarditis After COVID-19 mRNA Booster Vaccination.
Professor C. Mueller (Basel, CH)
Slides Video
Presentation thumbnail
Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial .
Doctor R. Furtado (Sao Paulo, BR)
Slides Video

Access the full session

Session thumbnail
Latest science in COVID and vaccination
Video

The Event

Event poster

ESC Congress 2022

28 August 2022 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin
thumbnail
Congress Presentation
Risk of major cardiovascular events and bleeding in atrial fibrillation patients with chronic obstructive pulmonary disease treated with low dose azithromycin prophylaxis.
thumbnail
Congress Presentation
Incidence, patient characteristics, and treatment patterns of U.S. active-duty service members diagnosed with COVID-19-associated VTE in the outpatient setting

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources